why choose us

First received: November 23, 2022

Clinical Trial: Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Atherosclerotic Cardiovascular Disease

Study Type: Observational


Official Title: Impact of Optimal Pharmacotherapy on Plasma Lipid Profile and Qualitative Features of Atherosclerotic Plaques in Very-high Cardiovascular Risk Patients With Established Atherosclerotic Cardiovascular

Brief Summary: Lipid accumulation, with mostly emphasized role of low-density lipoprotein cholesterol (LDL-C), is the pathogenetic cornerstone of atherosclerotic cardiovascular disease. Standard hypolipidemic therapy, based on statins and ezetimibe, does not always decrease LDL-C levels enough to achieve therapeutic goals. A novel and promising direction is inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepatocytes, subsequently reducing LDL-C receptor degradation and increasing intracellular LDL-C…

Read more